Chinese Academic Center Investigations Reveals Regulatory Factor 5 Expression in Non-Small Cell Lung Cancer

Aug 24, 2019 | China, Jiangsu Province 210029

doctor supervisor looking at the microscope slide in the forensic,Laboratory Medical scientists working at lab with test tubes researcher performs liquid,Laboratory concept with medical icon

Prominent Chinese academic medical centers conducted a study focusing on the mechanism of non-small cell lung cancer to find new therapeutic targets. The study reveals the transcription factor E2F1 positively regulates IRF5 in non-small cell lung cancer.

The Problem

Lung cancer is the most common malignant tumor in the world, and its incidence and mortality are very high. China is experiencing a dangerously growing rate of lung cancer. The incidence and mortality rates of lung cancer, the leading cause of cancer death in China, have significantly increased in recent years, and present geographic and gender differences as a result of diversity in lifestyles and socioeconomic development. A series of attribute risk analyses have shown that factors such as smoking, air pollution, and occupational factors are all related to lung cancer. Behavioral intervention, such as smoking cessation and screening, could effectively reduce lung cancer incidence and mortality.

The Study

The study focuses on the mechanism of non-small cell lung cancer to find new therapeutic targets. The team used RT-PCR and Western Blot to verify linear relationships between E2F1 and IRF5 in normal lung tissue and lung cancer tissues. Thereafter they used overexpression and knockdown E2F1 in cell lines to detect the expression of IRF5. The prime enzyme reporter plasmid verified that E2F1 binds to the core promoter region of IRF5—finally CHIP experiments demonstrated that E2F1 binds to IRF5.

Results

The team verified that E2F1 and IRF5 are decreased in patient tissues, and there is a strong linear relationship between E2F1 and IRF5. Secondly, they used overexpression of E2F1 or E2F1 siRNA transfected into HCC827 cells and found that E2F1 positively regulates the activity of the IRF5 promoter and the mRNA level of IRF5. Finally, the results of a chromatin immunoprecipitation assay demonstrated that E2F1 bound to the promoter region of IRF5 in vitro. These results suggested that the E2F1 transcription factor is the primary determinant for activating the basal transcription of the IRF5. The transcription factor E2F1 positively regulates IRF5 in non-small cell lung cancer.

Clinical Investigator Sites

  • Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
  • Department of Pediatrics, Children’s Hospital of Soochow University, Soochow University, Suzhou, Jiangsu Province 215025, China
  • Department of Chest Surgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China

Call to Action

If a patient, researcher or industry sponsor is interested in connecting with this research group we include the name and email of the lead researcher from First Affiliated Hospital, Nanjing Medical University, Nanjing, China

Lead Clinical Research/Investigator

Guo-Ping Zhou, Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China

Email: gpzhou2017@126.com

0 Comments

Pin It on Pinterest